Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
More than 40 years after publication of the U niversity G roup D iabetes P rogram trial, the cardiovascular safety of sulphonylureas is still contentious. Although several hypotheses linking sulphonylureas to adverse cardiovascular effects exist, none provide conclusive evidence. Adding to the controversy, current clinical trials and observational studies provide inconsistent, and sometimes conflicting, evidence for the cardiovascular effects of sulphonylureas. Overall, observational evidence suggests that an increased risk of adverse cardiovascular outcomes is associated with sulphonylureas; however, these data may be subject to residual confounding and bias. Although evidence from randomized controlled trials has suggested a neutral effect, the majority of these studies were not specifically designed to assess the effect of sulphonylureas on adverse cardiovascular event risk. Current ongoing large clinical trials may provide some clarity on the cardiovascular safety of sulphonylureas, but the results are not expected for several years. With the continued uncertainties concerning the cardiovascular safety of all antidiabetic drugs, a clear answer with regard to sulphonylureas is warranted. The objectives of the present article were to provide an overview of the controversy surrounding sulphonylurea‐related cardiovascular effects, to discuss the limitations of the current literature, and to provide recommendations for future studies aiming to elucidate the true relationship between sulphonylureas and adverse cardiovascular effects in people with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The ACCORD, ADVANCE and VADT trials were not designed or powered to test the safety of one antidiabetic agent against another.”
BackgroundEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675 · cited 1×
“These findings, coupled with findings of neutral associations from other smaller studies [17–19], seemed to put the sulphonylurea controversy to rest, with no clear evidence for cardiovascular risk; however, in 2007, amid reports of increased cardiovascular death and myocardial infarction with thiazolidinediones [20],…”
ResultRandomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a663cc · Cited by 1,128 · cited 1×
“Despite the use of advanced and complex analytical techniques, such as high-dimensional propensity-score matching [54] and instrumental variable adjustment [55], observational studies can only control for confounding variables that are identifiable in the available databases [56].”
MethodAssociation of Hypoglycemia and Cardiac Ischemia
Desouza, C., Salazar, H., Cheong, B., Murgo, J., & Fonseca, V. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1485 · Cited by 406 · cited 1×
“This response leads to increased myocardial oxygen consumption that might cause myocardial ischaemia [85–87] and precipitate QT prolongation and arrhythmia [86,88].”
BackgroundHong, J., Zhang, Y., Lai, S., Lv, A., Su, Q., Dong, Y., Zhou, Z., Tang, W., Zhao, J., Cui, L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-0719 · Cited by 366 · cited 2×
“Since the publication of the UGDP, only one long-term clinical trial specifically designed to assess cardiovascular outcomes in people randomized to sulphonylureas has been published [38].”
BackgroundVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 1×
“Experimental hypoglycaemia also seems to be associated with a pro-coagulant state, impaired vascular relaxation, and endothelial dysfunction [89,90].”
BackgroundA Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events
Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., & Clase, C. M. (2007) · Diabetes Care · doi:10.2337/dc06-1789 · Cited by 308
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Selvin, E., Bolen, S., Yeh, H.-C., Wiley, C., Wilson, L. M., Marinopoulos, S. S., Feldman, L., Vassy, J., Wilson, R., Bass, E. B., et al. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.19.2070 · Cited by 300 · cited 2×
“, 2008 [33] RCT (5) SU vs no SU Cardiovascular morbidity 0.”
BackgroundEvans, J. M. M., Ogston, S. A., Emslie-Smith, A., & Morris, A. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0176-9 · Cited by 293
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial
The ORIGIN Trial Investigators, Mellbin, L. G., Rydén, L., Riddle, M. C., Probstfield, J., Rosenstock, J., Díaz, R., Yusuf, S., & Gerstein, H. C. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht332 · Cited by 247
Simpson, S. H. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050748 · Cited by 235 · cited 1×
“[101] is the only one published to date that has examined the dose–response relationship between sulphonylureas and risk of adverse cardiovascular events.”
BackgroundIncreased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus
Landstedt‐Hallin, L., Englund, A., Adamson, U., & Lins, P. ‐. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00528.x · Cited by 141 · cited 1×
“This response leads to increased myocardial oxygen consumption that might cause myocardial ischaemia [85–87] and precipitate QT prolongation and arrhythmia [86,88].”
BackgroundThe UGDP Controversy: thirty-four years of contentious ambiguity laid to rest
Schwartz, T. B., & Meinert, C. L. (2004) · Perspectives in Biology and Medicine · doi:10.1353/pbm.2004.0071 · Cited by 85
Cited by
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 286
Do sulphonylureas still have a place in clinical practice?
Khunti, K., Chatterjee, S., Gerstein, H. C., Zoungas, S., & Davies, M. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30025-1 · Cited by 116
Scheen, A. J. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.009 · Cited by 18
Metadata
- Authors
- Abdelmoneim, A. S., Eurich, D. T., Light, P. E., Senior, P. A., Seubert, J. M., Makowsky, M. J., & Simpson, S. H.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-03-20
- Volume
- 17
- Issue
- 6
- Pages
- 523-532
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2043551382
- Cited by
- 78
- References
- 14
- FWCI
- 9.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.